Imatinib Grindeks (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR kinases. By preventing these enzymes from phosphorylating downstream proteins, the drug interrupts signaling pathways that promote cell proliferation and survival, leading to reduced tumor growth and increased cancer cell death.

The dose of Imatinib Grindeks is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the exact dosing regimen provided by their healthcare professional.

Safety data for Imatinib in pregnancy and lactation are limited, and the drug is classified as having an unknown pregnancy category. It is generally avoided unless the potential therapeutic benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception.

To place an order, submit an enquiry on the Imatinib Grindeks product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine kinase inhibitor and remains a standard first‑line option for CML and Ph+ ALL. Newer TKIs such as dasatinib and nilotinib have higher potency and may be used in cases of resistance or intolerance, but they also carry distinct safety profiles. Choice of therapy depends on disease characteristics, patient comorbidities and physician judgment.

Imatinib Grindeks should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Imatinib Grindeks is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber. The tablets should be swallowed whole and not crushed or chewed unless directed by a healthcare professional.

Serious adverse events include hepatotoxicity (elevated liver enzymes or hepatitis), cardiotoxicity such as congestive heart failure, severe neutropenia or other cytopenias, and significant bleeding episodes. Patients should report symptoms like jaundice, shortness of breath, unusual bruising or persistent fever to their physician promptly.

Imatinib Grindeks is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. It should also be avoided in patients with severe hepatic impairment or uncontrolled cardiac disease unless the prescribing clinician determines that the benefits outweigh the risks.